Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBITDA (2016 - 2025)

China Pharma Holdings filings provide 16 years of EBITDA readings, the most recent being -$1.0 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 26.84% to -$1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.9 million, a 39.93% increase, with the full-year FY2025 number at -$2.9 million, up 39.93% from a year prior.
  • EBITDA hit -$1.0 million in Q4 2025 for China Pharma Holdings, down from -$594147.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$270654.0 in Q1 2023 to a low of -$1.5 million in Q2 2022.
  • Median EBITDA over the past 5 years was -$977654.0 (2022), compared with a mean of -$956892.8.
  • Biggest five-year swings in EBITDA: crashed 3502.33% in 2021 and later soared 72.32% in 2023.
  • China Pharma Holdings' EBITDA stood at -$836967.0 in 2021, then fell by 29.12% to -$1.1 million in 2022, then dropped by 2.37% to -$1.1 million in 2023, then decreased by 29.03% to -$1.4 million in 2024, then increased by 26.84% to -$1.0 million in 2025.
  • The last three reported values for EBITDA were -$1.0 million (Q4 2025), -$594147.0 (Q3 2025), and -$508104.0 (Q2 2025) per Business Quant data.